Dublin, Dec. 14, 2017 -- The "Flat-Rate Access to R&D Database & Reports from La Merie Publishing" newsletter has been added to Research and Markets' offering.
A one-year subscription to this product provides 24/7 online access to both services from the publisher with a 30% discount on the list prices for all license types. Internet access is the only prerequisite for this service.
Upon purchase of the Flat-Rate Access to R&D Database & Reports from La Merie Publishing, credentials to access the database and a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.
1) Flat-Rate Subscription to La Merie Publishing Reports & News Services
A one-year subscription to this service provides access to:
- all existing reports on stock and listed online in the store;
- all new reports released by the publisher during the term of the subscription;
- 12 (monthly) issues of three different R&D and Business Tracking services;
- 50 (weekly) issues of R&D Pipeline News
Among the publisher's reports are:
- Competitor Analysis reports in tabular presentation format;
- Brief Reports; and Full Reports.
A full listing of existing reports can be found in the online store. Publishing activities include updates of existing reports as well as release of new reports.
Among the publisher's News & Information Services are:
- R&D and Business Tracker for TCR & CAR T-Cells and NK Cells;
- R&D and Business Tracker for Bispecific Antibodies;
- R&D and Business Tracker for Antibody-Drug Conjugates;
- R&D Pipeline News - Technology Edition;
- R&D Pipeline News - Therapeutic Area Edition.
For more information about this newsletter visit https://www.researchandmarkets.com/research/lptd5n/one_off_flatrate?w=12
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Pharmaceuticals


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Washington Post Publisher Will Lewis Steps Down After Layoffs
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Samsung Electronics Shares Jump on HBM4 Mass Production Report
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 



